"Biostatistics is an art, and like any art, it is open to interpretation," said David Miller, CEO of independent research firm Biotech Stock Research LLC.

Detailed data from the first Phase III trial of Human Genome Sciences Inc.'s lupus drug Benlysta (belimumab) lived up to expectations, boosting analyst confidence in the outcome of a second Phase III trial to be revealed Nov. 2. (BioWorld Today)